Join the Bupivacaine group to help and get support from people like you.
Bupivacaine News
FDA Medwatch Alert: Hospira Recalls 0.5% Bupivacaine Injection and 1% Lidocaine Injection, Due to Mislabeling
Hospira, Inc., a Pfizer company, is voluntarily recalling lot EG6023 of 0.5% Bupivacaine Hydrochloride Injection, USP 30 mL and lot EG8933 of 1% Lidocaine HCl Injection, USP 30 mL, to the...
FDA Approves Posimir (bupivacaine) for Post-Surgical Pain Reduction for up to 72 Hours Following Arthroscopic Subacromial Decompression
CUPERTINO, Calif., Feb. 2, 2021 /PRNewswire/ – DURECT Corporation (Nasdaq: DRRX) today announced that the U.S. Food and Drug Administration (FDA) has approved Posimir (bupivacaine solution) for...
FDA Approves Xaracoll (bupivacaine hydrochloride) Implant for Acute Postsurgical Pain Relief Following Open Inguinal Hernia Repair
ATHLONE, Ireland, Aug. 31, 2020 /PRNewswire/ — Innocoll Holdings Limited, a specialty pharmaceutical company and portfolio business of Gurnet Point Capital, announced today that the US Food and Drug A...
FDA Medwatch Alert: Implanted Pumps: Safety Communication - Use Caution When Selecting Pain Medicine for Intrathecal Administration
ISSUE: The FDA is aware that patients undergoing treatment or management of pain are commonly given pain medicines in the spinal fluid (intrathecal administration) that are not FDA approved for use...
Pacira Announces FDA Approval of Exparel as a Nerve Block to Produce Regional Analgesia
PARSIPPANY, N.J., April 06, 2018 (GLOBE NEWSWIRE) – Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental new drug...
FDA Medwatch Alert: 0.25 Percent Bupivacaine Hydrochloride Injection, USP by Hospira: Recall - Particulate Matter
ISSUE: Hospira, Inc., a Pfizer company, is voluntarily recalling one lot of 0.25% Bupivacaine Hydrochloride Injection, USP (NDC: 0409-1159-02, Lot 59-064- DK, Expiry 1NOV2017) at the hospital/retail...
FDA Medwatch Alert: Sensorcaine-MPF (bupivacaine HCl) by Fresenius Kabi: Recall - Presence of Particulate Matter
ISSUE: Fresenius Kabi USA announced today it is voluntarily recalling a single lot (Lot Number 6111504; Product Code 470237) of Sensorcaine®-MPF (bupivacaine HCl) Injection, USP, 0.75%, 7.5 mg/mL, 30 ...
FDA Medwatch Alert: Bupivacaine HCl Injection by Hospira: Recall - Iron Oxide Particulate In Glass Vials
ISSUE: Hospira issued a voluntary recall of one lot of Preservative-Free Bupivacaine HCl Injection, USP, 0.5% (5 mg/mL), 30 mL Single-dose (NDC: 0409-1162-02, Lot 38-515-DK, Expiry 1FEB2016) due to...
FDA Medwatch Alert: Marcaine (Bupivacaine HCI Injection, USP) 0.25 percent, 10 ml, Single-Dose, Preservative-Free Vial: Recall - Visible Particulates
[Posted 04/22/2014] ISSUE: Hospira, Inc. announced a voluntary nationwide recall to the user level for one lot of 0.25% Marcaine (Bupivacaine HCl Injection, USP), 10 mL, Single-dose Vial – P...
FDA Medwatch Alert: Hospira brand Lidocaine and Marcaine: Recall - Presence Of Particulate
UPDATED 10/21/2013 with related product recall information Hospira announced a voluntary nationwide recall to the user level for one lot of 0.25% Marcaine (Bupivacaine HCl Injection, USP), 75 mg/30...
Pacira Pharmaceuticals, Inc. Announces U.S. FDA Approval of Exparel For Postsurgical Pain Management
PARSIPPANY, N.J., Oct. 31, 2011 /PRNewswire via COMTEX/ – Pacira Pharmaceuticals, Inc. announces that the U.S. Food and Drug Administration (FDA) has approved Exparel (bupivacaine liposome...
Ask a question
To post your own question to this support group, sign in or create an account.